Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome

Andrews, Christopher N.; Griffiths, Tanya A. M.; Kaufman, Jaime; Vergnolle, Nathalie; Surette, Michael G.; Rioux, Kevin P.

doi:10.1111/j.1365-2036.2011.04732.x

Cited by 87 publications

(62 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be acknowledged that differences between the microbial communities may partly be the consequence of the use of anti-inflammatory drugs, since a recent study showed that melsalazine affected the fecal bacterial community composition in patients with inflammatory bowel syndrome (2). In the present study, four out of six UC patients in remission received melsalazine, whereas all the UC patients in relapse received the drug.…”

Section: Discussionmentioning

confidence: 62%

In Vitro Fermentation of Sugar Beet Arabino-Oligosaccharides by Fecal Microbiota Obtained from Patients with Ulcerative Colitis To Selectively Stimulate the Growth of Bifidobacterium spp. and Lactobacillus spp

Vigsnæs

Holck

Meyer

et al. 2011

Appl Environ Microbiol

View full text Add to dashboard Cite

The potential prebiotic properties of arabino-oligosaccharides (AOS) derived from sugar beet pulp was studied using mixed cultures of human fecal bacteria from patients with ulcerative colitis (UC), in remission or with active disease, and in healthy controls. These results were compared to those for fructo-oligosaccharides (FOS), which are known to have a prebiotic effect. Fermentation studies were carried out using a small-scale static batch system, and changes in the fecal microbial communities and metabolites were monitored after 24 h by quantitative real-time PCR and short-chain fatty acid analysis. With a few minor exceptions, AOS affected the communities similarly to what was seen for FOS. Quantitative real-time PCR revealed thatBifidobacteriumspp. andLactobacillusspp. were selectively increased after fermentation of AOS or FOS by fecal microbiota derived from UC patients. The stimulation of growth ofLactobacillusspp. andBifidobacteriumspp. was accompanied by a high production of acetate and hence a decrease of pH. The fermentation of AOS may help improve the inflammatory conditions in UC patients through stimulation of bacteria eliciting anti-inflammatory responses and through production of acetate. AOS may therefore represent a new prebiotic candidate for reduction of the risk of flare-ups in UC patients. However, human trials are needed to confirm a health-promoting effect.

show abstract

Section: Discussionmentioning

confidence: 62%

In Vitro Fermentation of Sugar Beet Arabino-Oligosaccharides by Fecal Microbiota Obtained from Patients with Ulcerative Colitis To Selectively Stimulate the Growth of Bifidobacterium spp. and Lactobacillus spp

Vigsnæs

Holck

Meyer

et al. 2011

Appl Environ Microbiol

View full text Add to dashboard Cite

show abstract

“…In a 20-patient study, general well-being was improved, but the colonic symptoms did not change (56). In a trial involving 12 IBS-D patients, mesalazine (1.5 g, 2 times per day) was associated with symptomatic response of global relief, decreased number of days with discomfort, and increased bowel movement satisfaction in 8 patients (57). Mesalazine induced relief of pain and diarrhea in patients with these predominant symptoms in a third trial (58), but efficacy was not replicated in a recent small trial (59).…”

Section: Chronic Diarrheamentioning

confidence: 99%

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Camilleri¹

2013

J. Clin. Invest.

View full text Add to dashboard Cite

Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. IntroductionGastrointestinal motility and functional disorders result in either abnormal propulsion of content or excessive sensation of normal or abnormal functions in different regions of the gut. These conditions constitute about 40% of referrals to gastroenterologists, and they result in significant disease burden. Advances in clinical management of these disorders are based on understanding the basic mechanisms involved in sensorimotor and secretory functions, coupled with clinical investigation and trial methodology.The most frequent gastrointestinal motility and functional disorders are esophagitis, gastroparesis, chronic diarrhea, chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), and visceral pain. This review summarizes the pathophysiology, lists commonly used current medications, and focuses on pharmacological agents in development for each disorder. At present, several approved medications relieve constipation and diarrhea; the major unmet needs are in gastroparesis, OIC, and visceral pain.

show abstract

“…Dysbiosis has been illustrated in both patients with Crohn's disease (CD) and ulcerative colitis (UC) during remission [50][51][52]. Even standard IBD therapies can significantly alter the gut microbiome, evidenced by nearly a 50% reduction in the bacterial load with mesalamine (5-aminosalicylic acid, mesalazine) administration and also an amplification of the dysbiosis with antibiotics [52,53].…”

Section: Genetic and Microbial Interactions In Inflammatory Bowel Dismentioning

confidence: 99%

Nature vs. Nurture: The Gut Microbiome and Genetics in the Development of Gastrointestinal Disease

Ec¹,

Da²

2016

J Hepatol Gastroint Dis

View full text Add to dashboard Cite

show abstract

Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome

Abstract: SUMMARY BackgroundImbalances in gut luminal bacteria may contribute to the pathogenesis of irritable bowel syndrome (IBS).

Cited by 87 publications

References 47 publications

In Vitro Fermentation of Sugar Beet Arabino-Oligosaccharides by Fecal Microbiota Obtained from Patients with Ulcerative Colitis To Selectively Stimulate the Growth of Bifidobacterium spp. and Lactobacillus spp

In Vitro Fermentation of Sugar Beet Arabino-Oligosaccharides by Fecal Microbiota Obtained from Patients with Ulcerative Colitis To Selectively Stimulate the Growth of Bifidobacterium spp. and Lactobacillus spp

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Nature vs. Nurture: The Gut Microbiome and Genetics in the Development of Gastrointestinal Disease

Contact Info

Product

Resources

About